

Patient Name:

DOB:

LEQEMBITM **INDICATIONS CHECKLIST** This document is intended to help practitioners determine the appropriateness of LEQEMBI therapy,

This document is intended to help practitioners determine the appropriateness of LEQEMBI therapy, document clinical decision making, and support medical necessity. This guide is not intended to supersede guidance from the FDA, state/local licensing agencies, or other regulatory bodies. For complete information, refer to www.leqembi.com

Criteria for Indications & Use

 Diagnosis: G30.0 Alzheimer's Disease, Early Onset G30.1 Alzheimer's Disease, Late Onset G30.8 Other Alzheimer's Disease G30.9 Alzheimer's Disease, Unspecified G31.84 Mild Cognitive Impairment, So Stated 	← G30.X codes require secondary F02.8X code →	 F02.80 Dementia without behavioral disturbance F02.81 Dementia with behavioral disturbance
2 Confirmation of Beta-Amyloid (Aβ)	Pathology:	
Beta-amyloid PET Scan	CSF Analysis	
Date:	– OR Date:	
Result:		lt:
		(t-tau, p-tau, or p-tau:Aβ ratio)
3 Confirmation of Cognitive Impairment (Typically completed prior to diagnosis):		
Assessment Performed: Assessment Date:		
General Practitioner Assessment of Cogn	tion (GPCOG) 🛛 Mini-Me	ental Status Exam (MMSE)
□ Memory Impairment Screen (MIS) □ Mini-Cog™ □ Other:		
Result/Notes:		
Result/Notes:		
Result/Notes: Monitoring for Amyloid Related Im 	aging Abnormalities (/	ARIA)
	•••	ARIA) ate:
4 Monitoring for Amyloid Related Im	•••	
 Monitoring for Amyloid Related Im Recent brain MRI obtained prior to 	initiating therapy Da	ate:
 Monitoring for Amyloid Related Im Recent brain MRI obtained prior to Result: 	□ Negative	ate:(Within one year)



Notes:

Patient Name:

DOB: